Seven Eight Capital’s Takeda Pharmaceutical TAK Stock Holding History

Seven Eight Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,580	Closed	-$181K	–	606
2022 Q4	$181K	Buy	+11,580	New	+$162K	0.05%	378
2022 Q3	–	Sell	-14,772	Closed	-$207K	–	624
2022 Q2	$207K	Buy	14,772 +922	+7%	+$13.2K	0.08%	337
2022 Q1	$198K	Sell	13,850 -8,169	-37%	-$120K	0.03%	492
2021 Q4	$300K	Sell	22,019 -105,856	-83%	-$1.48M	0.05%	360
2021 Q3	$2.1M	Buy	127,875 +46,200	+57%	+$776K	0.2%	177
2021 Q2	$1.38M	Buy	+81,675	New	+$1.39M	0.19%	179
2020 Q3	–	Sell	-17,820	Closed	-$320K	–	647
2020 Q2	$320K	Sell	17,820 -2,980	-14%	-$53.5K	0.23%	179
2020 Q1	$316K	Buy	20,800 +7,126	+52%	+$129K	0.08%	305
2019 Q4	$270K	Sell	13,674 -27,000	-66%	-$517K	0.01%	588
2019 Q3	$700K	Buy	40,674 +30,600	+304%	+$529K	0.04%	476
2019 Q2	$178K	Buy	+10,074	New	+$183K	0.01%	555

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Seven Eight Capital's TAK Position: Q1 2023 in Review

Seven Eight Capital sold out of Takeda Pharmaceutical (TAK) in Q1 2023, closing a stake of 11,580 shares — an estimated $181K sold.

Seven Eight Capital first reported a position in TAK in Q2 2019 and held it in 11 quarters. The position peaked at $2.1M in Q3 2021. 300 funds tracked by Wall St. Rank hold TAK as of Q1 2023.

Seven Eight Capital reported no remaining Takeda Pharmaceutical position as of Q1 2023 after selling out during the quarter.
Seven Eight Capital sold 11,580 Takeda Pharmaceutical shares in Q1 2023, an estimated $181K.
Seven Eight Capital first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 11 quarters.
Seven Eight Capital's Takeda Pharmaceutical position peaked at $2.1M in Q3 2021.
300 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2023.

Based on Seven Eight Capital's 13F filing for Q1 2023, filed 15 May 2023.